Advanced Hepatocellular Carcinoma Hcc clinical trials

Explore recruiting advanced hepatocellular carcinoma hcc clinical trials.

Recruiting advanced hepatocellular carcinoma hcc studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Advanced Hepatocellular Carcinoma Hcc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A prospective, randomized, placebo-controlled, double-blind, multicenter phase III registration clinical study to compare toripalimab (JS001) combined with lenvatinib versus placebo combined with lenvatinib as the 1st-line therapy for advanced hepatocellular carcinoma (HCC)

Poland, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2 Study of Tremelimumab (Day 1 only), Durvalumab (MEDI4736) and Trans-arterial catheter chemoembolization (TACE)in patients with advanced Hepatocellular Carcinoma (HCC)

Ireland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with advanced Hepatocellular Carcinoma (HIMALAYA)

Spain, Germany, France, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

CA209-9DW - A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma

Belgium, Poland, France, Spain, Romania, Italy +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Multi-Center, Double-Blind, Randomized, Phase III Study to Investigate the Efficacy and Safety of CS1003 in Combination with Lenvatinib Compared to Placebo in Combination with Lenvatinib as First-Line Therapy in Subjects with Advanced Hepatocellular Carcinoma (HCC)

Poland, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A study to assess the safety and anti-tumor activity of T cell therapy in subjects with advanced liver cancer or any other AFP expressing tumor types

Spain, France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Advanced Hepatocellular Carcinoma Hcc trials by city

Advanced Hepatocellular Carcinoma Hcc clinical trials

Recruiting advanced hepatocellular carcinoma hcc studies right now

Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC

Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma

A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC

SBRT With Atezo/Bev for HCC

A Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC Patients

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma

Ligufalimab and Cadonilimab in Advanced Liver Cancers

A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma

Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC

Also recruiting in Europe

A prospective, randomized, placebo-controlled, double-blind, multicenter phase III registration clinical study to compare toripalimab (JS001) combined with lenvatinib versus placebo combined with lenvatinib as the 1st-line therapy for advanced hepatocellular carcinoma (HCC)

A Phase 2 Study of Tremelimumab (Day 1 only), Durvalumab (MEDI4736) and Trans-arterial catheter chemoembolization (TACE)in patients with advanced Hepatocellular Carcinoma (HCC)

A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with advanced Hepatocellular Carcinoma (HIMALAYA)

CA209-9DW - A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma

A Multi-Center, Double-Blind, Randomized, Phase III Study to Investigate the Efficacy and Safety of CS1003 in Combination with Lenvatinib Compared to Placebo in Combination with Lenvatinib as First-Line Therapy in Subjects with Advanced Hepatocellular Carcinoma (HCC)

A study to assess the safety and anti-tumor activity of T cell therapy in subjects with advanced liver cancer or any other AFP expressing tumor types

Advanced Hepatocellular Carcinoma Hcc trials by city

Other conditions